Contribution margins and utilization of transcatheter aortic valve replacement versus surgical aortic valve replacement in the Medicare population

IF 3.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS American heart journal Pub Date : 2024-11-27 DOI:10.1016/j.ahj.2024.11.010
Kriyana P. Reddy BS , Kaitlyn Shultz MS , Lauren A. Eberly MD, MPH , Sameed Ahmed M. Khatana MD, MPH , Alexander C. Fanaroff MD, MHS , Dharam J. Kumbhani MD, SM , Sammy Elmariah MD, MPH , Paul Fiorilli MD , Howard Herrmann MD , Nimesh D. Desai MD, PhD , Pavan Atluri MD , Wilson Y. Szeto MD , Fenton McCarthy MD , David J. Cohen MD, MS , Peter W. Groeneveld MD, MS , Jay Giri MD, MPH , Ashwin S. Nathan MD, MS
{"title":"Contribution margins and utilization of transcatheter aortic valve replacement versus surgical aortic valve replacement in the Medicare population","authors":"Kriyana P. Reddy BS ,&nbsp;Kaitlyn Shultz MS ,&nbsp;Lauren A. Eberly MD, MPH ,&nbsp;Sameed Ahmed M. Khatana MD, MPH ,&nbsp;Alexander C. Fanaroff MD, MHS ,&nbsp;Dharam J. Kumbhani MD, SM ,&nbsp;Sammy Elmariah MD, MPH ,&nbsp;Paul Fiorilli MD ,&nbsp;Howard Herrmann MD ,&nbsp;Nimesh D. Desai MD, PhD ,&nbsp;Pavan Atluri MD ,&nbsp;Wilson Y. Szeto MD ,&nbsp;Fenton McCarthy MD ,&nbsp;David J. Cohen MD, MS ,&nbsp;Peter W. Groeneveld MD, MS ,&nbsp;Jay Giri MD, MPH ,&nbsp;Ashwin S. Nathan MD, MS","doi":"10.1016/j.ahj.2024.11.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Hospitals and health systems must balance the demand for transcatheter aortic valve replacement (TAVR) against financial sustainability. Patients may be eligible for both TAVR and surgical aortic valve replacement (SAVR), but financial realities for hospitals may affect differential access to those therapies. We sought to understand the landscape of costs and reimbursement for TAVR and SAVR in the US and to understand the association of procedural reimbursement with receipt of either.</div></div><div><h3>Methods</h3><div>We included fee-for-service Medicare beneficiaries undergoing isolated TAVR or SAVR in 2016-2019. For each TAVR and SAVR, inpatient revenues and direct costs were calculated at the claim level. The contribution margin (CM) for each TAVR or SAVR was then calculated as total revenues minus total direct costs, which defines the net profit for the procedure for the hospital. Multivariate logistic regressions were used to identify hospital characteristics associated with positive TAVR CMs. Multivariate linear regression was used to assess the relationship between relative volume of TAVR cases and relative differences in TAVR versus SAVR CMs at the hospital level.</div></div><div><h3>Results</h3><div>Of 542 sites, 377 (69.6%) had positive CMs, and 165 (30.4%) had negative CMs for TAVR; 505 (93.2%) had positive CMs for SAVR. Median revenues, costs, and CMs for TAVR decreased between 2016 and 2019. The median (IQR) total CM per hospital for TAVR decreased from $10,574 ($1,331-$22,259) in 2016 to $6,744 ($6,099-$17,511) in 2019 (P &lt; 0.001). Teaching hospital status (aOR 1.77, 95% CI 1.07-2.93) and for-profit status (aOR 3.7, 95% CI 1.8-7.6) were associated with increased odds of positive TAVR CMs relative to nonteaching hospital status and nonprofit status, respectively, in multivariate logistic regression models. The median (IQR) proportion of TAVR of total AVR was 76.67% (69.6%-82.5%) compared with 74.6% (66.9%-80.4%) at hospitals with negative TAVR CMs (<em>P</em> = .04). There was no significant linear relationship between hospital-level difference in median TAVR and SAVR CMs and hospital-level proportion of TAVR of total AVR in multivariate models.</div></div><div><h3>Conclusions</h3><div>Most hospitals had positive CMs for TAVR and nearly all had positive CMs for SAVR. Positive CMs for TAVR for individual hospitals were associated with a significant increase in the utilization of TAVR. However, the magnitude of difference in TAVR versus SAVR CM was not associated with differential procedural use.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"281 ","pages":"Pages 59-70"},"PeriodicalIF":3.7000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002870324003028","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Hospitals and health systems must balance the demand for transcatheter aortic valve replacement (TAVR) against financial sustainability. Patients may be eligible for both TAVR and surgical aortic valve replacement (SAVR), but financial realities for hospitals may affect differential access to those therapies. We sought to understand the landscape of costs and reimbursement for TAVR and SAVR in the US and to understand the association of procedural reimbursement with receipt of either.

Methods

We included fee-for-service Medicare beneficiaries undergoing isolated TAVR or SAVR in 2016-2019. For each TAVR and SAVR, inpatient revenues and direct costs were calculated at the claim level. The contribution margin (CM) for each TAVR or SAVR was then calculated as total revenues minus total direct costs, which defines the net profit for the procedure for the hospital. Multivariate logistic regressions were used to identify hospital characteristics associated with positive TAVR CMs. Multivariate linear regression was used to assess the relationship between relative volume of TAVR cases and relative differences in TAVR versus SAVR CMs at the hospital level.

Results

Of 542 sites, 377 (69.6%) had positive CMs, and 165 (30.4%) had negative CMs for TAVR; 505 (93.2%) had positive CMs for SAVR. Median revenues, costs, and CMs for TAVR decreased between 2016 and 2019. The median (IQR) total CM per hospital for TAVR decreased from $10,574 ($1,331-$22,259) in 2016 to $6,744 ($6,099-$17,511) in 2019 (P < 0.001). Teaching hospital status (aOR 1.77, 95% CI 1.07-2.93) and for-profit status (aOR 3.7, 95% CI 1.8-7.6) were associated with increased odds of positive TAVR CMs relative to nonteaching hospital status and nonprofit status, respectively, in multivariate logistic regression models. The median (IQR) proportion of TAVR of total AVR was 76.67% (69.6%-82.5%) compared with 74.6% (66.9%-80.4%) at hospitals with negative TAVR CMs (P = .04). There was no significant linear relationship between hospital-level difference in median TAVR and SAVR CMs and hospital-level proportion of TAVR of total AVR in multivariate models.

Conclusions

Most hospitals had positive CMs for TAVR and nearly all had positive CMs for SAVR. Positive CMs for TAVR for individual hospitals were associated with a significant increase in the utilization of TAVR. However, the magnitude of difference in TAVR versus SAVR CM was not associated with differential procedural use.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
经导管主动脉瓣置换术与外科主动脉瓣置换术在医疗保险人群中的应用。
背景:医院和卫生系统必须平衡经导管主动脉瓣置换术(TAVR)的需求和财务可持续性。患者可能同时符合TAVR和外科主动脉瓣置换术(SAVR)的条件,但医院的财务状况可能会影响这些治疗方法的差异。我们试图了解美国TAVR和SAVR的成本和报销情况,并了解程序报销与收到两者的关系。方法:我们纳入了2016-2019年接受孤立TAVR或SAVR的按服务收费的医疗保险受益人。对于每个TAVR和SAVR,住院收入和直接成本在索赔水平上计算。然后计算每个TAVR或SAVR的贡献边际(CM)为总收入减去总直接成本,这定义了医院的手术净利润。采用多变量logistic回归来确定与TAVR阳性CMs相关的医院特征。采用多元线性回归评估TAVR病例的相对数量与TAVR与SAVR CMs在医院水平上的相对差异之间的关系。结果:542个站点中CMs阳性377个(69.6%),TAVR阴性165个(30.4%);505例(93.2%)为SAVR阳性。2016年至2019年期间,TAVR的收入、成本和CMs中位数均有所下降。每家医院TAVR的总CM中位数(IQR)从2016年的10,574美元(1,331美元至22259美元)下降到2019年的6,744美元(6,099美元至17,511美元)(p结论:大多数医院TAVR CM阳性,几乎所有医院SAVR CM阳性。个别医院TAVR阳性CMs与TAVR使用率显著增加相关。然而,TAVR与SAVR CM的差异大小与手术使用的差异无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American heart journal
American heart journal 医学-心血管系统
CiteScore
8.20
自引率
2.10%
发文量
214
审稿时长
38 days
期刊介绍: The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.
期刊最新文献
Table of Contents Editorial Board Information for Readers Occult cancer in patients with unprovoked venous thromboembolism: Rationale, design, and methods of the ValRIETEs study and the SOME-RIETE trial. Design, rationale, and characterization of the Mobile health based OccuPational cardiovascular risk intErventioN study (mHealth-OPEN Study).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1